Startups want to biosynthesize CBD – Axios

AXIOS SUMMARY

Axios’s author Bryan Walsh highlighted the importance of Biosynthetically produced cannabinoids over traditionally cultivated cannabinoids. Dennis O’Neill of Biomedican also shared our unique approach -Biosynthesis of Cannabinoids- in the same article “Startups want to biosynthesize CBD”. The rapidly growing cannabis market started a race of various companies to produce cannabinoids biosynthetically.

The rapidly booming market of non-psychoactive compound CBD demands a cheaper and controllable method of cannabinoid production. The biosynthesis method is preferred over the plant cultivation method to keep pace with the rapid demand for CBD. The market opportunity for biosynthesis is around $40 billion.

The old method to yield cannabinoids is time-consuming. This involves harvesting desired strains of the cannabis plant and extracting the most wanted chemical. The very low concentration of the most sought-after cannabinoids in these plants demanded more plant material and thus increased the cost to $50,000/kg of the compound. According to Dennis O’Neill, this traditional grow-harvest-extract method is a “backbreaking work,” and the product can be highly psychoactive.

The biosynthesis process is similar to beer brewing. Various microbes i.e yeast and bacteria are used in the fermentation process to yield a single cannabinoid. This allows harvesting the product each day at a low cost without contaminants. According to Dennis O’Neill, “We can harvest every day, as opposed to a plant that requires 55 days to grow,”

Bryan mentioned the opportunity to produce advanced biofuels by a method similar to the biosynthesis of cannabinoids. Various startups are in a race to produce biofuel that is relatively difficult to achieve compared to cannabinoids.

Biomedican is scaling up efforts to produce pharmaceutical-grade, 100% organic, non-GMO rare cannabinoids by biosynthesis method that have a 70-90% lower cost than plant cultivation method. It is important to know that the biosynthesis method developed by Biomedican produces identical compounds to those found in nature through the natural means of an organism’s biological processes. To learn more about our biosynthesis method please visit our website.

Saba IqbalAuthor posts

Dr. Saba Iqbal is a contributing writer for BioMedican. She's a clinical pharmacist turned writer. Dr. Saba's education includes a doctoral degree in pharmacy (Pharm D) from the University of Sargodha, Pakistan. In search of a career that would take advantage of her medical and pharmaceutical skills, Dr. Saba found medical writing – a career path a few medical students consider. In her journey "from a medical bench to pen," she has worked with several startups for many years managing content on biotech products, pharmaceuticals, drugs, devices, and techniques. While keeping up with the latest trends in medical writing, she aims to use her writing skills to clearly communicate complex scientific, medical, and health information to the potential investor and general audience.

Comments are disabled.